← NeOnc Technologies Holdings, Inc. Common Stock overview

NeOnc Technologies Holdings, Inc. Common Stock vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

NeOnc Technologies Holdings, Inc. Common Stock (NTHI)

Q3 202617 Jun – 6 Aug 2026

▲4

NeOnc's brain tumor drugs win first foreign clearances and near key data

First international regulatory clearance for NEO212 Abu Dhabi's health department authorized NeOnc to start a Phase 2 trial of NEO212, its oral brain tumor therapy. This is the program's first approval outside the U.S., opening a new region for testing and adding a fresh path toward eventual sales.
A brand-new regulatory milestone that expands the company's clinical reach and potential market.
Second Abu Dhabi clearance covers NEO100 and pediatric gliomas NeOnc received another Abu Dhabi IND for NEO100, allowing adult Phase 1 and 2 studies plus a path to test it in children with high-grade gliomas. This widens the number of patients and uses for its lead drug, raising its long-term sales potential.
A separate new authorization that broadens the NEO100 program into pediatrics and more trials.
FDA feedback clears CMC hurdle for NEO212 The FDA gave written feedback on how NeOnc makes NEO212, and the company decided it was enough to cancel a planned meeting. That removes a possible delay in the drug's manufacturing review, keeping the program on track toward later-stage testing.
A new regulatory step that reduces uncertainty around NEO212's path forward.
Phase 2a data for NEO100 due by end of July NeOnc's NEO100-01 study is fully enrolled, and topline Phase 2a results are expected by the end of July 2026. Positive data could boost confidence in the drug and attract partners or investors; disappointing results would hurt the stock.
A near-term catalyst that could swing the stock sharply depending on results.

July 202617 Jun – 6 Aug 2026

▲4

NeOnc's brain tumor drugs win first foreign clearances and near key data

First international regulatory clearance for NEO212 Abu Dhabi's health department authorized NeOnc to start a Phase 2 trial of NEO212, its oral brain tumor therapy. This is the program's first approval outside the U.S., opening a new region for testing and adding a fresh path toward eventual sales.
A brand-new regulatory milestone that expands the company's clinical reach and potential market.
Second Abu Dhabi clearance covers NEO100 and pediatric gliomas NeOnc received another Abu Dhabi IND for NEO100, allowing adult Phase 1 and 2 studies plus a path to test it in children with high-grade gliomas. This widens the number of patients and uses for its lead drug, raising its long-term sales potential.
A separate new authorization that broadens the NEO100 program into pediatrics and more trials.
FDA feedback clears CMC hurdle for NEO212 The FDA gave written feedback on how NeOnc makes NEO212, and the company decided it was enough to cancel a planned meeting. That removes a possible delay in the drug's manufacturing review, keeping the program on track toward later-stage testing.
A new regulatory step that reduces uncertainty around NEO212's path forward.
Phase 2a data for NEO100 due by end of July NeOnc's NEO100-01 study is fully enrolled, and topline Phase 2a results are expected by the end of July 2026. Positive data could boost confidence in the drug and attract partners or investors; disappointing results would hurt the stock.
A near-term catalyst that could swing the stock sharply depending on results.

Latest17 Jun – 6 Aug 2026

▲4

NeOnc's brain tumor drugs win first foreign clearances and near key data

First international regulatory clearance for NEO212 Abu Dhabi's health department authorized NeOnc to start a Phase 2 trial of NEO212, its oral brain tumor therapy. This is the program's first approval outside the U.S., opening a new region for testing and adding a fresh path toward eventual sales.
A brand-new regulatory milestone that expands the company's clinical reach and potential market.
Second Abu Dhabi clearance covers NEO100 and pediatric gliomas NeOnc received another Abu Dhabi IND for NEO100, allowing adult Phase 1 and 2 studies plus a path to test it in children with high-grade gliomas. This widens the number of patients and uses for its lead drug, raising its long-term sales potential.
A separate new authorization that broadens the NEO100 program into pediatrics and more trials.
FDA feedback clears CMC hurdle for NEO212 The FDA gave written feedback on how NeOnc makes NEO212, and the company decided it was enough to cancel a planned meeting. That removes a possible delay in the drug's manufacturing review, keeping the program on track toward later-stage testing.
A new regulatory step that reduces uncertainty around NEO212's path forward.
Phase 2a data for NEO100 due by end of July NeOnc's NEO100-01 study is fully enrolled, and topline Phase 2a results are expected by the end of July 2026. Positive data could boost confidence in the drug and attract partners or investors; disappointing results would hurt the stock.
A near-term catalyst that could swing the stock sharply depending on results.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.